Journey West: How One Small Chinese Firm Is Taking On The World
Global Place For Affordable AMD Option?
When it kicked off a pivotal study in 32 countries, a small Chengdu-based company stepped into unknown waters littered with challenges, ranging from lack of expertise to limited enthusiasm for a made in China new drug, from controls over foreign currency outflows to vetting investigators in foreign lands. But a strong early performance at home has given Kanghong confidence to take on big pharma and the world.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.
The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.